AMGN
Amgen Inc.
—
337.6 $
-4.0600 (%-1.19)
Previous Close: 341.66
Day Low₺334.0501
Day High₺345
AMGN: Amgen Inc. Financials
AMGN Income Statement
Total revenue
Net income
Gross margin TTM
70.8%
Operating margin TTM
29.06%
Net profit margin TTM
20.99%
Return on investment TTM
—
| Period end | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 |
|---|---|---|---|---|
| Total revenue | 36,741,000,000 | 33,424,000,000 | 28,190,000,000 | 26,323,000,000 |
| Operating income | 10,676,000,000 | 7,258,000,000 | 7,897,000,000 | 9,566,000,000 |
| Net income | 7,711,000,000 | 4,090,000,000 | 6,717,000,000 | 6,552,000,000 |
All line items
| Line item | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 |
|---|---|---|---|---|
| Total revenue | 36,741,000,000 | 33,424,000,000 | 28,190,000,000 | 26,323,000,000 |
| Cost of revenue | 10,729,000,000 | 12,858,000,000 | 8,415,000,000 | 6,406,000,000 |
| Gross profit | 26,012,000,000 | 20,566,000,000 | 19,775,000,000 | 19,917,000,000 |
| Research and development expenses | 6,974,000,000 | 5,964,000,000 | 4,784,000,000 | 4,434,000,000 |
| General and administrative expenses | 0 | 6,109,000,000 | 0 | 4,573,000,000 |
| Selling and marketing expenses | 0 | 987,000,000 | 0 | 841,000,000 |
| Selling, general and administrative expenses | 7,050,000,000 | 7,096,000,000 | 6,179,000,000 | 5,414,000,000 |
| Other expenses | 1,312,000,000 | 248,000,000 | 879,000,000 | 503,000,000 |
| Operating expenses | 15,336,000,000 | 13,308,000,000 | 11,842,000,000 | 10,351,000,000 |
| Cost and expenses | 26,065,000,000 | 26,166,000,000 | 20,293,000,000 | 16,757,000,000 |
| Net interest income | -2,755,000,000 | -3,155,000,000 | -2,875,000,000 | -1,406,000,000 |
| Interest income | 0 | 0 | 0 | 0 |
| Interest expense | 2,755,000,000 | 3,155,000,000 | 2,875,000,000 | 1,406,000,000 |
| Depreciation and amortization | 5,167,000,000 | 5,592,000,000 | 4,071,000,000 | 3,417,000,000 |
| EBITDA | 16,898,000,000 | 13,356,000,000 | 14,801,000,000 | 12,169,000,000 |
| EBIT | 11,731,000,000 | 7,764,000,000 | 10,730,000,000 | 8,752,000,000 |
| Non-operating income (excl. interest) | -1,055,000,000 | -506,000,000 | -2,833,000,000 | 814,000,000 |
| Operating income | 10,676,000,000 | 7,258,000,000 | 7,897,000,000 | 9,566,000,000 |
| Total other income/expenses (net) | -1,700,000,000 | -2,649,000,000 | -42,000,000 | -2,220,000,000 |
| Income before tax | 8,976,000,000 | 4,609,000,000 | 7,855,000,000 | 7,346,000,000 |
| Income tax expense | 1,265,000,000 | 519,000,000 | 1,138,000,000 | 794,000,000 |
| Net income from continuing operations | 7,711,000,000 | 4,090,000,000 | 6,717,000,000 | 6,552,000,000 |
| Net income from discontinued operations | 0 | 0 | 0 | 0 |
| Other adjustments to net income | 0 | 0 | 0 | 0 |
| Net income | 7,711,000,000 | 4,090,000,000 | 6,717,000,000 | 6,552,000,000 |
| Net income deductions | 0 | 0 | 0 | 0 |
| Bottom line net income | 7,711,000,000 | 4,090,000,000 | 6,717,000,000 | 6,552,000,000 |
| EPS | 14 | 8 | 13 | 12 |
| Diluted EPS | 14 | 8 | 12 | 12 |
| Weighted average shares outstanding | 538,000,000 | 541,000,000 | 535,000,000 | 538,000,000 |
| Weighted average diluted shares outstanding | 542,000,000 | 541,000,000 | 538,000,000 | 541,000,000 |